Article

Tecartus for Mantle Cell Lymphoma Demonstrates Positive Data in Latest Study

Three-year follow-up analysis shows that Gilead’s car T-cell therapy induced high rates of durable response and a median overall survival of 46.6 months.

Kite, a Gilead Company, has released positive longer-term follow-up results from 2 pivotal studies of the CAR T-cell therapy Tecartus (brexucabtagene autoleucel).

The 3-year follow-up of ZUMA-2, a global, multi-center, phase 2 study evaluating the efficacy of Tecartus in patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL), and 2-year follow-up of ZUMA-3, a global, multi-center, open-label, single-arm phase 1/2 study evaluating Tecartus in adult patients with R/R B-cell acute lymphoblastic leukemia (B-ALL) were both presented during a poster session at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting. Three-year follow-up data from ZUMA-2 were also simultaneously published in ASCO’s Journal of Clinical Oncology.

“We are very encouraged by the totality of these data, which suggest a significant and sustained response with Tecartus for people living with difficult-to-treat blood cancers like MCL and B-ALL,” Frank Neumann, MD, PhD, senior vice president and global head of clinical development at Kite said in a statement. “These longer-term results add to the growing maturity of data on Kite’s CAR T-cell therapies.”

At a median of 35.6 of follow-up in the ZUMA-2 trial, the overall response rate (ORR) was 91%, with 68% of treated patients achieving a complete response (CR; 95% CI, 55.2–78.5). The median duration of response (DOR) was 28.2 months, with 37% of treated patients in ongoing response at data cut-off. Median overall survival (OS) among treated patients was 46.6 months. Among those patients who achieved a CR, the median OS has not yet been reached, with the 30-month OS rate at 60.3%. Late relapse, classified as more than 24 months post-infusion, was infrequent (n=3).

“There remains a significant need among patients living with MCL for therapies that provide a long-term response, as many patients have high-risk disease that is more likely to relapse or progress following multiple lines of treatment,” Michael Wang, MD, ZUMA-2 Lead Investigator and Puddin Clarke Endowed Professor, Department of Lymphoma and Myeloma, division of cancer medicine at The University of Texas MD Anderson Cancer Center, said in the statement. “The 3-year data from ZUMA-2 represent the longest follow-up for a CAR T-cell therapy in MCL patients to date and are impressive in their demonstration of brexu-cel to elicit durable long-term responses.”

In the ZUMA-3 trial, longer follow-up of the pivotal analysis and outcomes of a newly conducted larger pooled analysis of phase 1 and 2 patients by independent review who received the pivotal dose of Tecartus were reported. Most patients in the analysis were heavily pre-treated, with a median of 2 prior therapies, and 47% had received 3 or more prior therapies. At a median follow-up of 29.7 months for pooled phase 1 and 2 patients, 73.1% of treated patients achieved a CR or CR with incomplete hematological recovery (CRi). Median OS was 25.4 months for both phase 2-treated patients and pooled phase 1 and 2 treated patients. At data cutoff, median OS had not yet been reached in phase 2 patients who achieved a CR. Similar outcomes among phase 2 treated patients (n=55) and the pooled analysis of phase 1 and 2 patients (n=78) were observed.

Reference

Tecartus® Car T-cell therapy demonstrates strong overall survival rates and continued durable responses in long-term follow-up of two pivotal studies including longest ever follow-up of a CAR T-cell therapy in mantle cell lymphoma. Gilead. News release. June 4, 2022. Accessed June 5, 2022. https://www.gilead.com/news-and-press/press-room/press-releases/2022/6/tecartus-car-t-cell-therapy-demonstrates-strong-overall-survival-rates-and-continued-durable-responses-in-long-term-follow-up-of-two-pivotal-studies

Related Videos
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
Image Credit: © Krakenimages.com - stock.adobe.com
Image Credit: © Cavan - stock.adobe.com
Child with cancer -- Image credit: Alexis Scholtz/peopleimages.com | stock.adobe.com